Topic: National Cancer Research Network; Subtopic: Renal Cancer; Disease: Kidney research hub

A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and ECOG Performance Status 2 (PaZ02)

This study is testing a targeted cancer drug called pazopanib for advanced kidney cancer. It specifically welcomes people who feel tired or weak from their illness and need to rest during the day. Researchers want to see how safe the drug is and how well it controls cancer growth.